STOCK TITAN
  1. Home
  2. News
  3. DTIL

Precision BioSciences, Inc. - DTIL STOCK NEWS

Welcome to our dedicated page for Precision BioSciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision BioSciences stock.

Precision BioSciences, Inc., based in Durham, North Carolina, is a pioneering biotechnology company dedicated to enhancing life through advanced genome editing. The company employs its proprietary genome editing platform, ARCUS, to develop innovative product candidates aimed at treating human diseases and offering solutions in food and agriculture.

ARCUS, distinguished by its compact size, enables the delivery of gene edits to a broader range of cells and tissues using both viral and non-viral methods. This versatility makes it a robust tool in Precision BioSciences' mission to address various health conditions and agricultural challenges.

The company has recently made significant strides in its projects, partnering with multiple organizations to expand its research and product development capabilities. These collaborations have been pivotal in propelling forward the potential applications of ARCUS technology.

Precision BioSciences is actively engaged in several cutting-edge projects that underscore its commitment to innovation. The company's financial health is reflected in its consistent investment in research and development, ensuring sustained growth and advancement in its technology.

Latest News:

  • Source: iECURE, Inc.
  • Source: Precision BioSciences, Inc.
  • Source: Precision BioSciences
News

Precision BioSciences to Present at Hep-DART 2023

Rhea-AI Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) will present at Hep-DART 2023 in Los Cabos, Mexico, showcasing their PBGENE-HBV Program for gene editing therapies to potentially cure chronic hepatitis B. Presenters include Jeff Smith, Co-Founder and Chief Research Officer, and Emily Harrison, HBV Research Lead.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.05%
Tags
conferences
-
News

Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) announced the approval of an inducement award for a new employee under the 2021 Employment Inducement Incentive Award Plan. The award consists of a stock option to purchase 160,000 shares of Precision's common stock at an exercise price of $0.42 per share, with a 10-year term and vesting over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.53%
Tags
none
-
News

Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023

Rhea-AI Summary
DTIL - Precision BioSciences, Inc. presents late-breaking data at AASLD's The Liver Meeting on PBGENE-HBV, demonstrating up to 99% viral engagement and final clinical candidate readiness for CTA and/or IND filing in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.5%
Tags
none
News

Precision BioSciences to Present at Upcoming Sidoti Conference

Rhea-AI Summary
Precision BioSciences, Inc. (DTIL) to Present at Sidoti November Micro Cap Conference on November 15, 2023. The company will showcase its gene editing therapies utilizing the ARCUS® platform. The presentation details are available on Precision’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
conferences
-
News

Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Rhea-AI Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) announced that an abstract featuring preclinical data for its PBGENE-HBV program has been accepted for late-breaker presentation at the American Association for the Study of Liver Diseases Annual Meeting. The company will host a webcast and conference call on November 13, 2023, to discuss program updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
none
-
News

Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) announced financial results for Q3 2023, focusing on in vivo gene editing pipeline, strategic transaction with Imugene, and extended cash runway through 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
earnings
News

Precision BioSciences to Report Third Quarter Results on November 7, 2023

Rhea-AI Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) will publish its financial results for the third quarter 2023 and provide a business update on November 7, 2023. The company utilizes its ARCUS® platform for advanced gene editing therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.55%
Tags
conferences earnings
-
News

Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Rhea-AI Summary
Precision BioSciences presents data on ARCUS gene editing platform at ESGCT Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
clinical trial
-
News

Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference

Rhea-AI Summary
Precision BioSciences to present at H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Rhea-AI Summary
Precision BioSciences announces acceptance of abstracts for poster presentations at the European Society of Gene & Cell Therapy Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.33%
Tags
conferences

FAQ

What is the current stock price of Precision BioSciences (DTIL)?

The current stock price of Precision BioSciences (DTIL) is $4.72 as of December 20, 2024.

What is the market cap of Precision BioSciences (DTIL)?

The market cap of Precision BioSciences (DTIL) is approximately 34.9M.

What does Precision BioSciences, Inc. do?

Precision BioSciences is a biotechnology company that uses its ARCUS genome editing platform to develop treatments for human diseases and provide agricultural solutions.

Where is Precision BioSciences, Inc. located?

The company is based in Durham, North Carolina, United States.

What is ARCUS?

ARCUS is Precision BioSciences' proprietary genome editing platform, known for its small size and ability to deliver gene edits to various cells and tissues.

What are some recent achievements of Precision BioSciences?

The company has advanced its product candidates and formed partnerships to expand its research and development, showcasing the potential of ARCUS technology.

What is the focus of Precision BioSciences' current projects?

The company is focused on developing treatments for human diseases and offering innovative solutions in food and agriculture through its genome editing platform.

How does ARCUS differ from other genome editing tools?

ARCUS is unique due to its relatively small size, which allows it to target a wider range of cells and tissues using both viral and non-viral delivery methods.

Who are some partners of Precision BioSciences?

Precision BioSciences collaborates with organizations like iECURE, Inc. to enhance its research and development capabilities.

What kind of financial strategy does Precision BioSciences employ?

The company consistently invests in research and development to drive growth and technological advancement.

What is the significance of Precision BioSciences' work in agriculture?

The company aims to provide agricultural solutions that can improve food production and sustainability through advanced genome editing.

How does Precision BioSciences contribute to human health?

By developing innovative treatments for various diseases using its ARCUS genome editing platform, Precision BioSciences aims to improve patient outcomes and overall health.

Stock DTIL logo
Precision BioSciences, Inc.

Nasdaq:DTIL

DTIL Rankings

#5066 Ranked by Market Cap
N/A Ranked by Dividends

DTIL Stock Data

34.94M
6.59M
6.58%
44.7%
3.13%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
DURHAM